Asfand Y. Cheema

Hematology Oncology | Hematology | Oncology

4500 San Pablo Rd S
Jacksonville, FL 32224

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

BIO26-044: Utilization of a Population-Based Cox Analysis Model: Identifying Treatment Gaps and Demographic Influences on Overall Mortality in DLBCL.

BIO26-044: Utilization of a Population-Based Cox Analysis Model: Identifying Treatment Gaps and Demographic Influences on Overall Mortality in DLBCL.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 30, 2026

BPI26-014: Predictors of Advanced-Stage DLBCL at Diagnosis: Logistic Regression Analysis Highlights High Risk Populations With Inclusion of Demographic and Anatomic Risk Factors.

BPI26-014: Predictors of Advanced-Stage DLBCL at Diagnosis: Logistic Regression Analysis Highlights High Risk Populations With Inclusion of Demographic and Anatomic Risk Factors.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 29, 2026

HSR26-219: Site-Treatment Interactions Drive DLBCL-Specific Mortality: Machine Learning Analysis Reveals Attenuated Chemotherapy Benefits in Extranodal Disease.

HSR26-219: Site-Treatment Interactions Drive DLBCL-Specific Mortality: Machine Learning Analysis Reveals Attenuated Chemotherapy Benefits in Extranodal Disease.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 16, 2026

EPR26-178: Disease-Specific Mortality in DLBCL: Cox Model Reveals Superior Prognostic Value Over Age-Based Risk Assessments.

EPR26-178: Disease-Specific Mortality in DLBCL: Cox Model Reveals Superior Prognostic Value Over Age-Based Risk Assessments.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 16, 2026

BPI26-014: Predictors of Advanced-Stage DLBCL at Diagnosis: Logistic Regression Analysis Highlights High Risk Populations With Inclusion of Demographic and Anatomic Risk Factors.

BPI26-014: Predictors of Advanced-Stage DLBCL at Diagnosis: Logistic Regression Analysis Highlights High Risk Populations With Inclusion of Demographic and Anatomic Risk Factors.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 01, 2026

HSR26-219: Site-Treatment Interactions Drive DLBCL-Specific Mortality: Machine Learning Analysis Reveals Attenuated Chemotherapy Benefits in Extranodal Disease.

HSR26-219: Site-Treatment Interactions Drive DLBCL-Specific Mortality: Machine Learning Analysis Reveals Attenuated Chemotherapy Benefits in Extranodal Disease.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 01, 2026

EPR26-178: Disease-Specific Mortality in DLBCL: Cox Model Reveals Superior Prognostic Value Over Age-Based Risk Assessments.

EPR26-178: Disease-Specific Mortality in DLBCL: Cox Model Reveals Superior Prognostic Value Over Age-Based Risk Assessments.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 31, 2026

BIO26-044: Utilization of a Population-Based Cox Analysis Model: Identifying Treatment Gaps and Demographic Influences on Overall Mortality in DLBCL.

BIO26-044: Utilization of a Population-Based Cox Analysis Model: Identifying Treatment Gaps and Demographic Influences on Overall Mortality in DLBCL.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

Safety of coronary sinus mapping and ablation in patients with cardiac resynchronization therapy.

Safety of coronary sinus mapping and ablation in patients with cardiac resynchronization therapy.

Journal: Heart rhythm

Published: December 09, 2025

Safety of coronary sinus mapping and ablation in patients with cardiac resynchronization therapy.

Safety of coronary sinus mapping and ablation in patients with cardiac resynchronization therapy.

Journal: Heart rhythm

Published: December 09, 2025

Response to "Comment on Under the Hood: Evidence-Based Review of Allogeneic Chimeric Antigen Receptor T Cells for Hematologic Malignancies.

Response to "Comment on Under the Hood: Evidence-Based Review of Allogeneic Chimeric Antigen Receptor T Cells for Hematologic Malignancies.

Journal: Transplantation and cellular therapy

Published: November 11, 2025

Impact of cardiometabolic health on treatment outcomes in early-stage triple-negative breast cancer receiving chemoimmunotherapy.

Impact of cardiometabolic health on treatment outcomes in early-stage triple-negative breast cancer receiving chemoimmunotherapy.

Journal: Breast cancer research and treatment

Published: October 20, 2025

Showing 1-12 of 27

Last Updated: 09/26/2026